In patients with first-time anterior STEMI undergoing primary PCI, MTP-131 did not significantly reduce infarct size by CK-MB area under the curve over 72 h compared with placebo.
In plain wordsIn people with a first heart attack treated with stenting, MTP-131 did not significantly reduce heart damage compared with placebo.
- Peptide
- Elamipretide (SS-31)
- Outcome
- No significant changeInfarct size by CK-MB AUC over 72 h
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 0.05 mg/kg/h · intravenous · 1 hAs given in this study (human).
Measurements
- CK-MB AUC 0-72 h
- 5785 ng h/mL
- placebo
- CK-MB AUC 0-72 h
- 5570 ng h/mL
- MTP-131
Source sentences
Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS).
1 context sentence(design, population, supporting numbers)
EMBRACE STEMI is a multicentre, randomized, double-blind Phase 2a trial that evaluated the efficacy and safety of MTP-131 vs. placebo infused at a rate of 0.05 mg/kg/h for 1 h among first-time anterior STEMI subjects undergoing primary percutaneous coronary intervention (PCI) for a proximal or mid l…